TGTX Aug 2024 21.000 call
| Previous close | 1.2500 |
| Open | 1.0000 |
| Bid | 0.6000 |
| Ask | 0.8000 |
| Strike | 21.00 |
| Expiry date | 2024-08-16 |
| Day's range | 1.0000 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 375 |
GlobeNewswireTG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links. Link to Poster Presentation: A Post-Marketing Study Evaluating the Presence an
Simply Wall St.Despite shrinking by US$192m in the past week, TG Therapeutics (NASDAQ:TGTX) shareholders are still up 131% over 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- GlobeNewswire
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee. Abstracts are now available online and can be accessed on the CM
